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ABSTRACT
Obesity, especially at mid-life, is a major risk
factor for atherosclerosis, insulin resistance and
the metabolic syndrome, which in turn contribute to coronary artery disease (CAD), Type 2
diabetes and Alzheimer’s disease (AD). The rise
in overweight and obesity in all societies is
prompting intense research into the causes and
effects of the condition. Obesity disrupts many
body systems including glucose and lipid metabolism, circadian rhythms and liver function. It
also causes or increases inflammation and oxidative stress. Within cells, the endoplasmic reticulum (ER) appears to be particularly susceptible to such metabolic disruption. Sirtuin 1 (Sirt1)
and leptin have received attention recently as
they are central regulatory factors for the body’s
metabolic pathways which interact at particular
levels, for example lipid and Abeta metabolism.
This mini-review discusses recent findings concerning obesity, lipid metabolism and the role of
Sirtuin 1 and how all influence the ER. A greater
understanding of obesity and its effects on metabolic control systems of the body are required,
to develop pharmacological, dietary and lifestyle
changes that will reduce the incidence of CAD,
Type 2 diabetes and AD.
Keywords: Obesity; Sirtuin 1; Alzheimer’s Disease;
Cardiovascular Disease; Diabetes

1. INTRODUCTION
Obesity is associated with an increased risk for atheroCopyright © 2012 SciRes.

sclerosis, contributing to the onset of coronary artery disease. Obesity is also well-known to be associated with
Type 2 diabetes, insulin resistance and hyperlipoproteinemia. In fact, obesity and the metabolic syndrome have
become major public health issues as they have reached
epidemic proportions in Western populations [1]. Obesity
is now recognized as an important risk factor for AD and
cognitive decline [2-10]. For example, in a study of 8534
individuals from the Swedish Twin Registry, it was found
that both overweight and obesity at midlife increase the
risk of dementia, AD, and vascular dementia [11,12], and
in an 18 year follow up study of overweight women, a
higher incidence of dementia (particularly AD) was found
in these women relative to controls [13]. Obesity and
overweight, as measured by body mass index and skin
fold thickness, has been strongly associated with AD and
dementia, independent of the development of diabetes
and cardiovascular disorders [6].

2. OBESITY AND ADIPOSITY
Obesity is defined as having a body mass (BMI) index
of >30 (BMI = weight in kg/[height in m]2), whereas
overweight is defined as having a BMI from 25 to 30.
Obesity is a medical condition in which excess body fat
has accumulated to such an extent that it is likely to have
adverse effects on life expectancy and leads to increased
health problems. Adiposity is the body fat tissue content,
and as the degree of adiposity increases, the level of adiposity can be defined as being overweight or obese by
measures such as the BMI.

3. MIDLIFE OBESITY
Being overweight or obese in early life or middle adult
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life leads to hyperinsulinemia which may lead to diabetes
later in life. Therefore the timing and the development of
adiposity is critical to the understanding how it is associated with the pathogenesis of AD (Figure 1).
In a recent longitudinal study of 1149 individuals, midlife obesity was found to be a significant risk factor for
AD in later life [14]. Abnormally high levels of the Abeta
peptide are believed to be involved in AD pathogenesis,
and in our own recent studies, we have found a strong
positive correlation between body fat and blood plasma
Abeta levels in cognitively normal individuals aged between 23 to 65 [15].

4. DIET AND RISK OF ALZHEIMER’S
DISEASE
Epidemiological studies have shown that people of similar ethnic origins yet living in different environments
can have significantly different risks of dementia [16,17].
Nigerians living in Africa have a much lower incidence
of AD when compared with African Americans living in
the US [16]. Similar results were obtained with Japanese
people living in Japan when compared with Japanese
Americans living in the US [17]. These differences were
believed to be mostly due to dietary differences. Diet and
dietary fat intake are now considered particularly important when comparing the lifestyles of populations screened for AD [18]. In support of obesity and caloric intake
influencing AD risk, for example, one study has found
that the more saturated fat consumed in a meal the greater the risk for developing AD and senile dementia [19].
In other studies of humans and other animals, it has been
found that feeding diets high in saturated fats results in
learning and memory impairments. High caloric intake
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of saturated fat has also been associated with greater cerebral Abeta amyloid deposition [19]. In contrast diets
containing chronically high levels of polyunsaturated fatty acids result in better learning when compared with diets containing saturated fat [20].
Cholesteryl esters can be hydrolysed in lysosomes
following which fatty acids become available for oxidative metabolism, in particular to carbon dioxide [21]. As
a result, the metabolism of dietary lipids can be assessed
using a stable isotope breath test [21] and using such a
test, the clearance and metabolism of cholesterol-rich
dietary lipoproteins in obese individuals has been found
to be markedly lower than normal, indicating that the
ingested fat was poorly cleared and metabolised from the
blood plasma. Obese individuals have high triglyceride
levels and low HDL levels with an increase in small LDL
particles [22,23]. In animal models of AD, strong correlations between high fat/high cholesterol diets and increases in brain Abeta levels and HDL cholesterol levels
and lower LDL cholesterol levels have been shown. For
example, increased cerebral Abeta deposition as well as
increased memory impairment has been shown in AD
model transgenic mice fed high fat diets, and although
exercise [24] and environmental enrichment [25] have
been shown to reverse these effects to some extent, when
translating to clinical situations, one major recommendation would always be to reduce saturated fat intake. Longitudinal studies have shown that people with an overall
lower calorie intake also have a reduced incidence of AD
later in life [13].
In obese individuals, there are several abnormalities in
free fatty acid (FFA) metabolism [26,27]. There is an increase in FFA release from adipose tissue to the blood
plasma which impairs the uptake of glucose by muscle

Figure 1. Obesity as a mechanism for induction of Alzheimer’s disease.
Copyright © 2012 SciRes.
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[26,27]. Furthermore, the rate of lipolysis is accelerated
in visceral adipose tissue and the increase in circulating
FFA results in dyslipidemia, hyperinsulinemia and hyperglycemia [28].
Essential fatty acids such as cis-linolenic acid (LA) and
alpha-linolenic acid are essential for humans, and the metabolism of these fatty acids is altered in obesity and other
diseases [29,30]. In AD individuals the composition of
phospholipid fatty acids is also altered [31] with increases
in saturated fatty acids (14:0, 16:0, 18:0) and decreases
in polyunsaturated fatty acids being found [31]. These
alterations in phospholipid fatty acid composition may be
associated with the high saturated fatty acid intake at midlife in AD individuals [32].

5. LEPTIN AND OBESITY
Leptin is a 16-kDa hormone that plays a key role in regulating energy intake and energy expenditure. It acts on
the hypothalamus to influence appetite and metabolism.
Leptin regulates lipid homeostasis and has also been
shown, in vitro and in vivo, to have important effects on
Abeta levels via apolipoprotein E-dependent pathways
[33]. It is secreted by adipose tissue and levels are usually directly proportional to the levels of body fat. Therefore, obese individuals have elevated leptin levels that is
related to their increased adipose tissue mass [33]. It appears that obese people are resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin [34].

6. INSULIN AND OBESITY
Insulin modulates cognition and other aspects of normal brain function. The insulin resistance syndrome is
characterized by chronic high levels of insulin, reduced
insulin activity and reduced brain insulin levels. Insulin
resistance together with obesity can lead to increases in
cardiovascular risk factors such as dyslipidemia, hypertension and Type 2 diabetes [35]. Insulin resistance is
also associated with age-related memory impairment and
an increased risk of Alzheimer’s disease. High insulin levels are known to increase the levels of Abeta and inflammatory changes that are linked to age and obesity [35,36].
For example, AD-model mouse studies have shown that
inducing type 2 diabetes caused an increase in Abeta production and Abeta neuropathology, impaired insulin receptor signal transduction, and a significant potentiation
of cognitive deterioration compared to non-diabetic control AD mice [37]. It has been suggested that the higher
levels of brain Abeta in such mice may be due to result
from the high insulin completely consuming insulin-degrading enzyme (IDE) activity–IDE can degrade both insulin and Abeta but has a preference for insulin thus resulting in elevated Abeta [38]. Preventing or correcting
Copyright © 2012 SciRes.

insulin abnormalities may reduce the risk of age related
memory impairment and AD.
High fat diets are known to interfere with glucose tolerance and insulin sensitivity and yet such detrimental
effects depend greatly on the type of fat consumed [3941]: saturated and trans-fatty acids increase insulin resistance whereas mono- and polyunsaturated fats decrease
resistance and protect against the disease.

7. SIRTUIN 1
The sirtuin proteins, also known as silent information
regulators, are class III histone deacetylases (HDAC).
Sirtuin 2 was the first to be identified: it was found to be
a mediator of replicative lifespan in budding yeast. It was
then shown to modulate longevity in worms and flies.
These protective actions are believed to result from the
beneficial regulation of stress management and energy
homeostasis [42-56]. Sirtuins are now known to regulate
several cell functions by deacetylating both histone and
non-histone targets.
The mammalian homologue, Sirtuin 1 (Sirt1), seems to
have evolved complex systemic roles in cardiac function,
DNA repair and genomic stability. Sirt1 has been shown
to play a central role in metabolic homeostasis. It is involved in gluconeogenesis in the liver, fat mobilisation
from white adipose tissue, cholesterol metabolism, insulin secretion from the pancreas and energy metabolism in
general [57]. For example, Sirt1 deacetylates and activates the transcriptional co-activator PGC1-alpha and the
transcription factor FoxO1 in the liver, to promote gluconeogenesis. In adipose tissue, Sirt1 triggers fat mobilisation by inhibiting peroxisome proliferator-activated receptor gamma (PPAR-gamma), and in the pancreas, Sirt1
repression of the uncoupling protein 2 (UCP2) increases
insulin secretion [58]. Sirt1 also influences mitochondrial
biogenesis, inflammation (cytokine release) and amyloidosis [42-56].
Calorie restriction has been shown to extend life span.
In fact, it has been shown to extend the median and maximum life span of numerous organisms including yeast,
flies, worms, fish, and rodents and mammals. It is now
believed that this may be mediated partly due to the increase in Sirt1 activity which is induced by calorie restriction. For example, increased Sirt1 activity mediates
mitochondrial biogenesis, which in turn may reduce the
production of reactive oxygen species, a possible cause
of aging and AD pathogenesis [59]. The involvement of
Sirt1 in insulin regulation as well as cholesterol, fatty acid
and glucose homeostasis has been linked to obesity, diabetes and cardiovascular disease. As these diseases are
all thought to increase risk of AD, this provides further
reason to believe that activating Sirt1 by calorie restriction may reduce the risk of AD (Figure 2) [60].
OPEN ACCESS
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Figure 2. Anti-aging protein Sirtuin 1 controls peripheral cholesterol & lipid homeostasis and brain amyloid beta metabolism; ER = endoplasmic reticulum, UPR = unfolded protein response, VLDL = very low density lipoprotein, HDL = high density
lipoprotein, PPAR = peroxisome proliferators-activated receptor.

The concept that diet can regulate adipocyte plasma
leptin (16 kda protein) as well as Sirt1 levels is supported
by reports that high fat diets can lead to leptin resistance
and low Sirt1 levels in rats and humans [57,61-64]. Brain
Sirt1 expression is increased by caloric restriction and fasting has been shown to increase brain Sirt1 protein content specifically in the hypothalamus. It also appears that
the effect of Sirt1 on energy balance is mediated through
central melanocortin signalling [58].
Recent studies suggest a functional relevance of SIRT1
in normal brain physiology, neurogenesis and neurological function [42-56]. In one important study for example,
Sirt1 was found to downregulate micro-RNA known as
miR-134. MiR-134 has been shown to down-regulate
cAMP response binding protein (CREB) and brain-derived neurotrophic factor (BDNF), thus reducing synaptic
plasticity. Sirt1 can prevent this miR-134-induced downregulation, thereby promoting synaptic plasticity [53].
Since 2005, miRNAs have been linked to complex metabolic processes in mammals, and changes to miRNAs can
occur in many metabolic abnormalities and disease conditions. For example obesity, hyperlipidemia (elevated
levels of blood lipids), and insulin resistance have been
shown to be associated with aberrant expression of multiple essential miRNAs in pancreatic islets of Langerhans
and peripheral tissues, including adipose tissue. Furthermore, in obese patients and experimental models of obesity such as 3T3-L1 preadipocytes and adipocytes from
leptin deficient mice (ob/ob: mouse model of insulin resistance and obesity) and diet-induced obese mice, miRNAs normally induced during adipogenesis are downregulated. In particular, miR-143, miR-103 and miR-107,
known to regulate adipocyte differentiation, are down-regulated in the ob/ob mice, possibly through an inflammatory pathway [65].
Copyright © 2012 SciRes.

8. SIRTUIN 1 AND THE AMYLOID
PRECURSOR PROTEIN (APP) OF
ALZHEIMER’S DISEASE
The maintenance of Sirt1 expression by calorie restriction has the effect of regulating lipid metabolism and
energy expenditure, which in turn helps regulate the production of many other proteins [54,55,57,66]. In obesity
however, Sirt1 levels are reduced and increased plasma
Abeta, leptin and body fat have all been shown to correlate with increased adipose tissue size (AT). It has also
been shown that Abeta precursor protein (APP) production is upregulated in adipocytes, and that plasma Abeta
levels correlate with these increased levels of APP [67].
The increased plasma Abeta is proposed to be due to obesity influencing peripheral Abeta clearance, as obesityin-duced Sirt1 dysregulation is strongly associated with
liver steatosis and decreased Aβ clearance by the liver
[15,33,57,66-69]. Under conditions of calorie restriction
on the other hand, Aβ content in the brain is attenuated,
and this effect can be reproduced in mouse neurons in
vitro by manipulating cellular SIRT1 expression/activity,
ultimately promoting the nonamyloidogenic α-secretase
processing of the APP, which precludes the generation of
Abeta [70]. In particular, the over-expression of SIRT1 in
the hippocampus has been shown to provide protection
against neurodegeneration in a mouse model of Alzheimer’s disease [71], and the over-expression of SIRT1 in
the brains of AD-model transgenic mice has been shown
to reduce brain Abeta production and amyloid deposition
in these mice, due to the induction of the α-secretase enzyme ADAM-10 [72]. In the arcuate nucleus of the hypothalamus, there are two types of neurons that play vital
roles in regulating feeding and energy expenditure: the
anorexigenic proopiomelanocortin (POMC) neurons and
OPEN ACCESS

1452

I. J. Martins et al. / Health 4 (2012) 1448-1456

the orexigenic agouti-related peptide (AgRP) neurons.
Sirt1 is expressed in both sets of neurons [51,73].
Alterations in circadian rhythms have been demonstrated in both obesity and AD, and alterations in Sirt1
expression and leptin levels have been associated with
this disruption to the daily light/dark cycle. Obese individuals are highly susceptible to circadian desynchrony,
especially if on a high fat and cholesterol diet which disrupts normal tissue Sirt1 regulation of cholesterol homeostasis [69,74-76]. PPARgamma, also known for its
extensive roles in glucose and lipid metabolism is now
emerging as a critical factor in the regulation of circadian
networks and it exhibits a circadian expression pattern
that is magnified by consumption of a high-fat diet [77].
PPARgamma has been implicated in the pathology of
several diseases including obesity, diabetes, atherosclerosis, and cancer, and PPARgamma agonists have been
used successfully in the treatment of dyslipidemia and
hyperglycemia. In support of Sirt1’s role in circadian
rhythms, a recent epidemiological study of Sirt1 and circadian locomotor output cycles kaput (CLOCK) genetics
found that subjects carrying minor alleles at SIRT1 and
CLOCK loci displayed a higher resistance to weight loss
compared with homozygotes for both major alleles, suggesting links between the circadian clock and Sirt1 function [73].
Other genetic studies are uncovering strong links between obesity and SIRT1 gene polymorphisms. For example, in a Japanese study, the A allele of SIRT1 polymorphism rs7895833, G allele of rs7069102, and T allele
of rs2273773 were found to pose a high risk for obesity
in men. Furthermore, the A allele of rs7895833 in women,
and the G allele of rs7069102 and C allele of rs2273773
in men, were found to carry a high risk for hypertension
[78]. In later studies by the same group, SIRT1 polymorphisms, rs7069102 and rs2273773, were found to be
associated with abnormal cholesterol metabolism and
coronary artery calcification, respectively, especially in
males [79]. Another recent study of French caucasian
adults found a strong association between high BMI and
the SIRT1 SNPs rs3395786 and rs11599176, whereas 4
SNPs studied in BMI-discordant siblings of Swedisn families were found to be associated with lower BMI [80].
In another study of the SIRT1 gene, a common SNP in a
novel p53-binding sequence in the human SIRT1 promoter was found to affect nutrient-sensitive SIRT1 expression, and thus could have a significant impact on SIRT1mediated changes in human metabolism and physiology
that are induced by calorie restriction [81]. In contrast, a
German study genotyped 1573 long-lived individuals
(centenarians and nonagenarians) and matched younger
controls, looking at five SIRT1 single nucleotide polythese polymorphisms on longevity [82]. Such genetic studies are providing a greater understanding of metabolic
Copyright © 2012 SciRes.

differences between people and why some individuals
may be more susceptible than others to obesity and related metabolic disturbances.

9. OBESITY, THE ENDOPLASMIC
RETICULUM AND ALZHEIMER’S
DISEASE
Common medical conditions that can occur in middle
age, such as diabetes, visceral obesity, and atherosclerosis
cause considerable stress to the body. Obesity and atherosclerosis are regarded as states of chronic low-grade inflammation. At the cellular level, inflammatory mediators
and lipid accumulation can evoke chronic stress, in particular affecting the endoplasmic reticulum (ER). It has recently been shown that the ER responds to metabolic
stress through a well-coordinated molecular response.
This involves the transcriptional activation of a variety of
genes, the attenuation of protein synthesis, the degradation of ER-localised misfolded proteins, and sometimes
the onset of apoptosis [83]. Disturbances in liver metabolism are known to be key components in the development of fatty liver, insulin resistance, and atherosclerosis.
It has been shown that SIRT1 helps to regulate lipid homeostasis by positively regulating peroxisome proliferators-activated receptor alpha (PPARalpha), a nuclear receptor that mediates the adaptive response to fasting and
starvation. This was demonstrated in liver-specific SIRT1
knockout mice, which when challenged with a high fat
diet, developed hepatic steatosis, hepatic inflammation,
and endoplasmic reticulum stress [46]. In these mice,
PPARalpha signalling was shown to be impaired and fatty
acid beta-oxidation was decreased. In other studies, the
overexpression of SIRT1 in the liver of diet-induced insulin-resistant low-density lipoprotein receptor-deficient
mice and of genetically obese ob/ob mice attenuates hepatic steatosis and ameliorates systemic insulin resistance.
These beneficial effects were associated with decreased
mammalian target of rapamycin complex 1 (mTORC1)
activity, inhibited unfolded protein response (UPR) and
enhanced insulin receptor signaling in the liver, leading
to decreased hepatic gluconeogenesis and improved glucose tolerance. These studies suggest that SIRT1 acts as a
negative regulator of UPR signalling in Type II diabetes,
and supports the concept that SIRT1 can attenuate hepatic steatosis, reduce insulin resistance, and restore glucose
homeostasis, largely through the inhibition of mTORC1
and ER stress [84]. In other recent studies of Sirt1 and
diabetes, SIRT1 in HepG2 cells has been shown to regulate ER stress by increasing expression of oxygen-related
protein 150 (ORP150), an inducible ER protein thought
to be a molecular chaperone involved in Ca2+ metabolism,
again supporting the concept that SIRT1 can ameliorate
insulin resistance via the regulation of ER stress [85].
OPEN ACCESS
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syndrome, mild cognitive impairment and Alzheimer’s
disease—The emerging role of systemic low-grade inflammation and adiposity. Brain Research Bulletin, 89,
144-149. doi:10.1016/j.brainresbull.2012.08.003

10. CONCLUSIONS
The potential influence of associations between obesity and Alzheimer’s disease pathogenesis has been of
great interest in recent research. High caloric intake and
the consumption of a diet rich in saturated fat have both
been associated with obesity, Type II diabetes, cardiovascular disease and Alzheimer’s disease. Sirt1 appears to
play a central role in many metabolic changes that have
been implicated in many of these conditions, as well as
in AD pathogenesis. Recent studies of Sirt1 and ER function suggest Sirt1 provides considerable protection against
metabolic stress via ER regulation.
Several studies have suggested that in early to midadult life, exercise and dietary interventions [86,87] such
as calorie restriction may prevent obesity as well as reduce or prevent amyloid deposition in the brain, due to
the resultant chronic activation of Sirt1 in tissues such as
the brain and the liver. When considering diet, omega −3
fatty acids are important for brain development, and fish
consumption has been associated with decreased cognitive deficits and a reduced risk for AD [88,89]. A diet
low in saturated fats and cholesterol, yet rich in fruit, vegetables, and omega −3 fatty acids may provide essential
micronutrients and antioxidants. Pharmaceutical treatments and/or other therapies centered around Sirt1 regulation might provide promising therapies in the treatment
of metabolic diseases including obesity. Studies have already provided support for this theory—for example, the
activation of Sirt1 by the polyphenol resveratrol and several synthetic pharmacologic activators has been shown
to protect against high-fat diet induced obesity and other
metabolic derangements. This is supported by studies
which have found that transgenic mice over-expressing
SIRT1 are leaner than controls, have a higher metabolism,
and have lower serum levels of cholesterol, insulin, and
glucose. Thus, calorie restriction, regular exercise, and/or
drug treatment in obesity or other disease state may maintain or restore normal SIRT1 gene function. The evidence suggests that this would ultimately stabilise lipid
metabolism and cause significant weight loss, reduce obesity and related disorders, as well as reduce or delay the
development of Alzheimer’s disease.
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